{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:49:37Z","timestamp":1788886177721,"version":"build-2803163510"},"reference-count":148,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Starting with imatinib, tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML) from a lethal blood cancer into a chronic condition. As patients with access to advanced CML care have an almost normal life expectancy, there is a perception that CML is a problem of the past, and one should direct research resources elsewhere. However, a closer look at the current CML landscape reveals a more nuanced picture. Most patients still require life-long TKI therapy to avoid recurrence of active CML. Chronic TKI toxicity and the high costs of the well-tolerated agents remain challenging. Progression to blast phase still occurs, particularly in socioeconomically disadvantaged parts of the world, where high-risk CML at diagnosis is common. Here, we review the prospects of further improving TKIs to achieve optimal suppression of BCR::ABL1 kinase activity, the potential of combining different classes of TKIs, and the current state of BCR::ABL1 degraders. We cover combination therapy approaches to address TKI resistance in the setting of residual leukemia and in advanced CML. Despite the unprecedented success of TKIs in CML, more work is needed to truly finish the job, and we hope to stimulate innovative research aiming to achieve this goal.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026312","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T18:53:41Z","timestamp":1735325621000},"page":"931-943","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Novel treatment strategies for chronic myeloid leukemia"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5849-8011","authenticated-orcid":false,"given":"Nataly","family":"Cruz-Rodriguez","sequence":"first","affiliation":[{"name":"1Versiti Blood Research Institute, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2987-1331","authenticated-orcid":false,"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[{"name":"1Versiti Blood Research Institute, Milwaukee, WI"},{"name":"2Department of Medicine, Division of Hematology\/Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"24","key":"2025032119423658700_bib1","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2025032119423658700_bib2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025032119423658700_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/hematology.2019000050","article-title":"Meeting the needs of CML patients in resource-poor countries","volume":"2019","author":"Malhotra","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"2025032119423658700_bib4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025032119423658700_bib5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"2025032119423658700_bib6","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2025032119423658700_bib7","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"20","key":"2025032119423658700_bib8","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025032119423658700_bib9","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025032119423658700_bib10","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","article-title":"Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u22651 prior tyrosine kinase inhibitor: 2-year follow-up results","volume":"38","author":"Cortes","year":"2024","journal-title":"Leukemia"},{"issue":"19","key":"2025032119423658700_bib11","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1182\/blood.2024024657","article-title":"Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study","volume":"144","author":"Yeung","year":"2024","journal-title":"Blood"},{"issue":"7647","key":"2025032119423658700_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"issue":"5","key":"2025032119423658700_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"2025032119423658700_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2025032119423658700_bib15","doi-asserted-by":"crossref","first-page":"2029999","DOI":"10.1080\/23723556.2022.2029999","article-title":"Resistance to kinase inhibition through shortened target engagement","volume":"9","author":"Rangwala","year":"2022","journal-title":"Mol Cell Oncol"},{"issue":"6","key":"2025032119423658700_bib16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","article-title":"Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis","volume":"14","author":"Shah","year":"2008","journal-title":"Cancer Cell"},{"issue":"16","key":"2025032119423658700_bib17","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood-2007-10-113969","article-title":"Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis","volume":"114","author":"Snead","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2025032119423658700_bib18","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2025032119423658700_bib19","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.clml.2023.05.009","article-title":"Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results","volume":"23","author":"Gener-Ricos","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025032119423658700_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol Res"},{"issue":"22","key":"2025032119423658700_bib21","doi-asserted-by":"crossref","first-page":"8227","DOI":"10.1021\/ja311756u","article-title":"Discovery of picomolar ABL kinase inhibitors equipotent for wild type and T315I mutant via structure-based de novo design","volume":"135","author":"Park","year":"2013","journal-title":"J\u00a0Am Chem Soc"},{"issue":"4","key":"2025032119423658700_bib22","first-page":"1267","article-title":"A\u00a0novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants","volume":"9","author":"Huron","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5682","key":"2025032119423658700_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"5","key":"2025032119423658700_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"31","key":"2025032119423658700_bib25","doi-asserted-by":"crossref","first-page":"17131","DOI":"10.1002\/anie.202105383","article-title":"Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL inhibitors","volume":"60","author":"Quach","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"issue":"26","key":"2025032119423658700_bib26","doi-asserted-by":"crossref","first-page":"e202203878","DOI":"10.1002\/anie.202203878","article-title":"Cell-active, reversible, and irreversible covalent inhibitors that selectively target the catalytic lysine of BCR-ABL kinase","volume":"61","author":"Chen","year":"2022","journal-title":"Angew Chem Int Ed Engl"},{"key":"2025032119423658700_bib27","article-title":"Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-\/dual-drug targeting strategies","author":"Sun","year":"2024","journal-title":"J\u00a0Adv Res"},{"issue":"1","key":"2025032119423658700_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase\u00a01\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"2025032119423658700_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"2025032119423658700_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.exphem.2019.08.007","article-title":"BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia","volume":"77","author":"Antelope","year":"2019","journal-title":"Exp Hematol"},{"issue":"suppl 1","key":"2025032119423658700_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2022-166452","article-title":"Efficacy and safety of vodobatinib in patients (pts) with chronic phase Philadelphia positive chronic myeloid leukemia (Ph+ CML): a sub group analysis by lines of tyrosine kinase inhibitor (TKI) therapy [abstract]","volume":"140","author":"Cortes","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119423658700_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-139847","article-title":"Phase 1 trial of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): activity in CML chronic phase patients failing TKI therapies including ponatinib [abstract]","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119423658700_bib33","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2023-181391","article-title":"Tgrx-678, a novel allosteric inhibitor of BCR-ABL1, demonstrates preclinical anti-leukemia activity, high oral bioavailability and synergism with ponatinib to suppress the highly resistant compound mutations [abstract]","volume":"142","author":"Shi","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119423658700_bib34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood-2023-185977","article-title":"Safety and efficacy of Tgrx-678, a potent BCR-ABL allosteric inhibitor in patients with tyrosine kinase inhibitor (TKI) resistant\/refractory chronic myeloid leukemia (CML): preliminary results of phase I study [abstract]","volume":"142","author":"Jiang","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119423658700_bib35","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1182\/blood-2023-182343","article-title":"Tern-701 (HS-10382) is a potent inhibitor of BCR::ABL1 and is synergistic with active site tyrosine kinase inhibitors [abstract]","volume":"142","author":"M Parsons","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2025032119423658700_bib36","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"issue":"9","key":"2025032119423658700_bib37","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 (T315I)-compound mutations","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"34","key":"2025032119423658700_bib38","doi-asserted-by":"crossref","first-page":"e2304611120","DOI":"10.1073\/pnas.2304611120","article-title":"A\u00a0biophysical framework for double-drugging kinases","volume":"120","author":"Kim","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"2025032119423658700_bib39","doi-asserted-by":"crossref","first-page":"18292","DOI":"10.1074\/jbc.M801337200","article-title":"Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib","volume":"283","author":"Vajpai","year":"2008","journal-title":"J\u00a0Biol Chem"},{"issue":"suppl 1","key":"2025032119423658700_bib40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/blood-2023-189270","article-title":"Asciminib (ASC) in combination with imatinib (IMA), nilotinib (NIL), or dasatinib (DAS) may be a potential treatment (Tx) option in patients (Pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase (Ph+ CML-CP\/AP): final results from the asciminib phase 1 study [abstract]","volume":"142","author":"Cortes","year":"2023","journal-title":"Blood"},{"issue":"24","key":"2025032119423658700_bib41","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"S3","key":"2025032119423658700_bib42","doi-asserted-by":"crossref","first-page":"e34543a6","DOI":"10.1097\/01.HS9.0000967536.34543.a6","article-title":"S156: frontline asciminib combination in chronic phase chronic myeloid leukemia patients","volume":"7","author":"Ernst","year":"2023","journal-title":"Hemasphere"},{"issue":"14","key":"2025032119423658700_bib43","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1080\/10428194.2021.1966787","article-title":"Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"62","author":"Zerbit","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2025032119423658700_bib44","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.ccell.2024.08.004","article-title":"Overcoming clinical BCR::ABL1 compound mutant resistance with combined ponatinib and asciminib therapy","volume":"42","author":"Eide","year":"2024","journal-title":"Cancer Cell"},{"issue":"3","key":"2025032119423658700_bib45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","article-title":"Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study","volume":"28","author":"Cortes","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2025032119423658700_bib46","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2025032119423658700_bib47","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"28","key":"2025032119423658700_bib48","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2025032119423658700_bib49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2025032119423658700_bib50","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ajh.26689","article-title":"Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"2025032119423658700_bib51","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17474086.2024.2370556","article-title":"Is 50 mg\/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?","volume":"17","author":"Saydan","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"2025032119423658700_bib52","doi-asserted-by":"crossref","first-page":"107542","DOI":"10.1016\/j.leukres.2024.107542","article-title":"Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: a comparative analysis of two prospective trials","volume":"143","author":"Shin","year":"2024","journal-title":"Leuk Res"},{"issue":"21","key":"2025032119423658700_bib53","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2025032119423658700_bib54","first-page":"117","article-title":"Structure of the Bcr-Abl oncoprotein oligomerization domain","volume":"9","author":"Zhao","year":"2002","journal-title":"Nat Struct Biol"},{"issue":"1","key":"2025032119423658700_bib55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1097-2765(03)00274-0","article-title":"Autoinhibition of Bcr-Abl through its SH3 domain","volume":"12","author":"Smith","year":"2003","journal-title":"Mol Cell"},{"issue":"26","key":"2025032119423658700_bib56","doi-asserted-by":"crossref","first-page":"24372","DOI":"10.1074\/jbc.M100786200","article-title":"Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization","volume":"276","author":"Smith","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"8","key":"2025032119423658700_bib57","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/leu.2015.53","article-title":"A\u00a0coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia","volume":"29","author":"Woessner","year":"2015","journal-title":"Leukemia"},{"issue":"27","key":"2025032119423658700_bib58","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1021\/acs.jpcb.4c02699","article-title":"Molecular modeling of single- and double-hydrocarbon-stapled coiled-coil inhibitors against Bcr-Abl: toward a treatment strategy for CML","volume":"128","author":"Lima","year":"2024","journal-title":"J\u00a0Phys Chem B"},{"key":"2025032119423658700_bib59","doi-asserted-by":"publisher","DOI":"10.1101\/2023.11.15.566894","article-title":"Computational modeling of stapled coiled-coil inhibitors against Bcr-Abl: toward a treatment strategy for CML","author":"Lima","year":"17  2023","journal-title":"bioRxiv"},{"issue":"14","key":"2025032119423658700_bib60","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1021\/acs.jpcb.8b01014","article-title":"Computational modeling of stapled peptides toward a treatment strategy for CML and broader implications in the design of lengthy peptide therapeutics","volume":"122","author":"Cornillie","year":"2018","journal-title":"J\u00a0Phys Chem B"},{"issue":"5","key":"2025032119423658700_bib61","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/0092-8674(95)90350-X","article-title":"Increased neutrophil respiratory burst in bcr-null mutants","volume":"80","author":"Voncken","year":"1995","journal-title":"Cell"},{"issue":"9","key":"2025032119423658700_bib62","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/s41375-024-02365-w","article-title":"BCR::ABL1 proteolysis-targeting chimeras (PROTACs): the new frontier in the treatment of Ph(+) leukemias?","volume":"38","author":"Cruz-Rodriguez","year":"2024","journal-title":"Leukemia"},{"issue":"15","key":"2025032119423658700_bib63","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/0008-5472.CAN-03-3656","article-title":"Effect of mutational inactivation of tyrosine kinase activity on BCR\/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors","volume":"64","author":"Ramaraj","year":"2004","journal-title":"Cancer Res"},{"issue":"4","key":"2025032119423658700_bib64","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/j.1460-2075.1993.tb05797.x","article-title":"An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias","volume":"12","author":"McWhirter","year":"1993","journal-title":"EMBO J"},{"issue":"10","key":"2025032119423658700_bib66","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"2025032119423658700_bib67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Hantschel","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"7","key":"2025032119423658700_bib68","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"111","author":"Wu","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2025032119423658700_bib69","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2025032119423658700_bib70","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/leu.2010.287","article-title":"Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia","volume":"25","author":"Samanta","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"2025032119423658700_bib71","first-page":"2316","article-title":"Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways","volume":"9","author":"Janmaat","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2025032119423658700_bib72","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2025032119423658700_bib73","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fonc.2019.00800","article-title":"Rethink of EGFR in cancer with its kinase independent function on board","volume":"9","author":"Thomas","year":"2019","journal-title":"Front Oncol"},{"issue":"5","key":"2025032119423658700_bib74","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccr.2008.03.015","article-title":"Survival of cancer cells is maintained by EGFR independent of its kinase activity","volume":"13","author":"Weihua","year":"2008","journal-title":"Cancer Cell"},{"issue":"736","key":"2025032119423658700_bib75","doi-asserted-by":"crossref","first-page":"eabg5216","DOI":"10.1126\/scisignal.abg5216","article-title":"Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK","volume":"15","author":"Dhami","year":"2022","journal-title":"Sci Signal"},{"issue":"8","key":"2025032119423658700_bib76","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1074\/jbc.RA119.011536","article-title":"Analyses of the oncogenic BRAF(D594G) variant reveal a kinase-independent function of BRAF in activating MAPK signaling","volume":"295","author":"Cope","year":"2020","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"2025032119423658700_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.str.2015.10.020","article-title":"Structural basis for the non-catalytic functions of protein kinases","volume":"24","author":"Kung","year":"2016","journal-title":"Structure"},{"issue":"29","key":"2025032119423658700_bib78","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"2025032119423658700_bib79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood-2017-10-810986","article-title":"Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response","volume":"132","author":"Bhatia","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2025032119423658700_bib81","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0896-6273(00)80646-7","article-title":"Essential roles for the Abl and Arg tyrosine kinases in neurulation","volume":"21","author":"Koleske","year":"1998","journal-title":"Neuron"},{"issue":"5","key":"2025032119423658700_bib82","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2021011802","article-title":"MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common \u03b2-chain cytokine receptor endocytosis","volume":"139","author":"Zhao","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2025032119423658700_bib83","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2020004834","article-title":"An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia","volume":"135","author":"Ko","year":"2020","journal-title":"Blood"},{"key":"2025032119423658700_bib84","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","article-title":"A\u00a0phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease","volume":"74","author":"Sweet","year":"2018","journal-title":"Leuk Res"},{"key":"2025032119423658700_bib85","volume-title":"European Hematology Association Annual Meeting 2024","author":"Sweet KO","year":"2024"},{"issue":"suppl 1","key":"2025032119423658700_bib86","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood-2019-130043","article-title":"Nilotinib vs nilotinib plus pegylated interferon \u03b1 (Peg-IFN) induction and nilotinib or Peg-IFN maintenance therapy for newly diagnosed BCR-ABL1 positive chronic myeloid leukemia patients in chronic phase (TIGER study): the addition of Peg-IFN is associated with higher rates of deep molecular response [abstract]","volume":"134","author":"Hochhaus","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2025032119423658700_bib87","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/leu.2015.45","article-title":"Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia","volume":"29","author":"Burchert","year":"2015","journal-title":"Leukemia"},{"issue":"22","key":"2025032119423658700_bib88","first-page":"2738","article-title":"A\u00a0single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia","volume":"141","author":"Krishnan","year":"2023","journal-title":"Blood"},{"key":"2025032119423658700_bib89","doi-asserted-by":"publisher","DOI":"10.1101\/2023.08.16.553504","article-title":"Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response","author":"Warfvinge","year":"18  2023","journal-title":"bioRxiv"},{"issue":"3","key":"2025032119423658700_bib98","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1073\/pnas.1213021110","article-title":"ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia","volume":"110","author":"Jiang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2025032119423658700_bib99","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"2025032119423658700_bib100","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41375-018-0252-4","article-title":"Targeting quiescent leukemic stem cells using second generation autophagy inhibitors","volume":"33","author":"Baquero","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"2025032119423658700_bib101","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41375-019-0700-9","article-title":"A\u00a0randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease","volume":"34","author":"Horne","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"2025032119423658700_bib102","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A\u00a0pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Goff","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"355","key":"2025032119423658700_bib103","doi-asserted-by":"crossref","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2016","journal-title":"Sci Transl Med"},{"issue":"15","key":"2025032119423658700_bib104","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/cncr.35317","article-title":"Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia","volume":"130","author":"Jabbour","year":"2024","journal-title":"Cancer"},{"issue":"11","key":"2025032119423658700_bib105","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1016\/S2352-3026(24)00250-3","article-title":"Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial","volume":"11","author":"Short","year":"2024","journal-title":"Lancet Haematol"},{"issue":"11","key":"2025032119423658700_bib106","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Hurtz","year":"2011","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"2025032119423658700_bib107","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.stem.2019.02.018","article-title":"Mesenchymal niche-specific expression of Cxcl12 controls quiescence of treatment-resistant leukemia stem cells","volume":"24","author":"Agarwal","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"11","key":"2025032119423658700_bib108","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov"},{"issue":"11","key":"2025032119423658700_bib109","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic myelogenous leukemia- initiating cells require polycomb group protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Cancer Discov"},{"issue":"7280","key":"2025032119423658700_bib110","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"issue":"7239","key":"2025032119423658700_bib111","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"issue":"3","key":"2025032119423658700_bib150","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"issue":"12","key":"2025032119423658700_bib112","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","article-title":"STAT5 signaling is required for the efficient induction and maintenance of CML in mice","volume":"107","author":"Ye","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2025032119423658700_bib113","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Traer","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"2025032119423658700_bib114","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in\u00a0vitro and in\u00a0vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119423658700_bib115","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/leusup.2014.3","article-title":"STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia","volume":"3","author":"Eiring","year":"2014","journal-title":"Leuk Suppl"},{"issue":"7","key":"2025032119423658700_bib116","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat Genet"},{"issue":"5","key":"2025032119423658700_bib117","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3324\/haematol.2019.219261","article-title":"Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem\/progenitor cells in a murine model","volume":"105","author":"Carter","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2025032119423658700_bib118","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41467-024-44771-9","article-title":"Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease","volume":"15","author":"Scott","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"2025032119423658700_bib119","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nm.4499","article-title":"Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat Med"},{"issue":"14","key":"2025032119423658700_bib120","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2017-05-783845","article-title":"hsa-mir183\/EGR1-mediated regulation of E2F1 is required for CML stem\/progenitor cell survival","volume":"131","author":"Pellicano","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2025032119423658700_bib121","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nat Med"},{"issue":"10","key":"2025032119423658700_bib122","doi-asserted-by":"crossref","first-page":"e56279","DOI":"10.15252\/embr.202256279","article-title":"Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells","volume":"24","author":"Rattigan","year":"2023","journal-title":"EMBO Rep"},{"issue":"1","key":"2025032119423658700_bib123","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/s41467-023-40222-z","article-title":"Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells","volume":"14","author":"Rattigan","year":"2023","journal-title":"Nat Commun"},{"issue":"751","key":"2025032119423658700_bib124","doi-asserted-by":"crossref","first-page":"eadi5336","DOI":"10.1126\/scitranslmed.adi5336","article-title":"Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia","volume":"16","author":"Khalaf","year":"2024","journal-title":"Sci Transl Med"},{"issue":"1","key":"2025032119423658700_bib125","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/s41467-024-46114-0","article-title":"Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1 mediated purine sensing","volume":"15","author":"Zarou","year":"2024","journal-title":"Nat Commun"},{"issue":"7307","key":"2025032119423658700_bib126","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nature09171","article-title":"Regulation of myeloid leukaemia by the cell-fate determinant Musashi","volume":"466","author":"Ito","year":"2010","journal-title":"Nature"},{"issue":"3","key":"2025032119423658700_bib127","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ccr.2013.01.025","article-title":"Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression","volume":"23","author":"Reavie","year":"2013","journal-title":"Cancer Cell"},{"issue":"7607","key":"2025032119423658700_bib128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"issue":"21","key":"2025032119423658700_bib129","doi-asserted-by":"crossref","first-page":"10482","DOI":"10.1073\/pnas.1903550116","article-title":"Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells","volume":"116","author":"Ma","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2025032119423658700_bib130","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0301-472X(02)00836-6","article-title":"In\u00a0vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia","volume":"30","author":"La Ros\u00e9e","year":"2002","journal-title":"Exp Hematol"},{"issue":"7198","key":"2025032119423658700_bib131","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature"},{"issue":"4","key":"2025032119423658700_bib132","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00432-024-05700-x","article-title":"Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes","volume":"150","author":"Tian","year":"2024","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"5","key":"2025032119423658700_bib133","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"2025032119423658700_bib134","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Neviani","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"427","key":"2025032119423658700_bib135","doi-asserted-by":"crossref","first-page":"eaan8735","DOI":"10.1126\/scitranslmed.aan8735","article-title":"PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL(+) human leukemia","volume":"10","author":"Lai","year":"2018","journal-title":"Sci Transl Med"},{"issue":"7569","key":"2025032119423658700_bib136","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"issue":"10","key":"2025032119423658700_bib137","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1172\/JCI85239","article-title":"Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia","volume":"126","author":"Jin","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"2025032119423658700_bib138","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-05-501072","article-title":"Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile","volume":"122","author":"Cramer-Morales","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2025032119423658700_bib139","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"issue":"7281","key":"2025032119423658700_bib140","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"issue":"6","key":"2025032119423658700_bib141","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in\u00a0vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"issue":"2","key":"2025032119423658700_bib142","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A\u00a0gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2025032119423658700_bib143","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"2","key":"2025032119423658700_bib144","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI45977","article-title":"CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression","volume":"122","author":"Schurch","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"25","key":"2025032119423658700_bib145","doi-asserted-by":"crossref","first-page":"E2298","DOI":"10.1073\/pnas.1301838110","article-title":"Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function","volume":"110","author":"Lim","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2025032119423658700_bib146","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2025032119423658700_bib147","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/leu.2015.196","article-title":"beta-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"29","author":"Eiring","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"2025032119423658700_bib148","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2016-05-714089","article-title":"Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI","volume":"129","author":"Agarwal","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2025032119423658700_bib149","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2025032119423658700_bib90","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2025032119423658700_bib91","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Adnan Awad","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2025032119423658700_bib92","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/s41467-021-23097-w","article-title":"Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia","volume":"12","author":"Ochi","year":"2021","journal-title":"Nat Commun"},{"issue":"22","key":"2025032119423658700_bib93","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"2025032119423658700_bib94","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S2352-3026(21)00370-7","article-title":"Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1\/2 trial","volume":"9","author":"Copland","year":"2022","journal-title":"Lancet Haematol"},{"key":"2025032119423658700_bib95","first-page":"S170","article-title":"Ponatinib and 5-azacytidine for the treatment of myeloid blast phase chronic myelogenous leukemia: results of the PONAZA trial [abstract]","author":"Rousselot","year":"2024","journal-title":"EHA Library"},{"issue":"1","key":"2025032119423658700_bib96","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","article-title":"Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia","volume":"101","author":"Burchert","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2025032119423658700_bib97","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/10428194.2024.2313626","article-title":"Stem cell allografting for chronic myeloid leukemia in the tyrosine kinase era - forgotten but not gone","volume":"65","author":"Tang","year":"2024","journal-title":"Leuk Lymphoma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/9\/931\/2357263\/blood_bld-2024-026312-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/9\/931\/2357263\/blood_bld-2024-026312-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:46:01Z","timestamp":1742589961000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/9\/931\/534848\/Novel-treatment-strategies-for-chronic-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":148,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026312","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}